Anatara Lifesciences is developing evidence based solutions for gastrointestinal diseases in humans and animals.

Introducing Anatara’s technology

GaRP is the working name for Anatara’s evidence based complementary medicines using unique formulations of bromelain, an enzyme extracted from pineapple stems along with other synergistic GRAS components. The combination and coating of these GaRP components have a beneficial effect on the physiology of the gastrointestinal lining, a positive influence on the microbiome (homeostasis & metabolites) and allows absorption of components in targeted areas of the gastrointestinal tract. GaRP’s multimodal activity provides a versatility for tailoring the components to various indications and we presently have in progress two human trials.

Human Applications

Anatara is developing proprietary formulations for gastrointestinal health.

Introducing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted complementary medicine

Anatara’s GaRP product is a microbiome-targeted multi-component complementary medicine that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

A new formulation, 3FDC, was developed using GaRP technology. 3FDC has been designed with 3 components with functional delivery coatings which are released in the large intestine (colon) to positively influence the gut-brain connection, targeting modulation of psychobiological processes driving anxiety-related disorders and to assist homeostasis of the “gut” to promote overall health and wellbeing.

Our pipeline products are being positioned as adjuncts to existing therapies, and will not be replacing current prescription medications. Over the last 20 years the use of complementary medicine as adjuncts to prescription drugs has increased significantly.

Our Human Applications page provides further information on our human development plans.

Anatara’s team and opportunity

Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health in humans.

Animal Applications

Non-antibiotic products for pigs and poultry

Anatara developed Detach® for the control of scour (diarrhoea) in pigs which was approved the Australian Pesticides and Veterinary Medicines Authority (APVMA) for this application.

Detach® has been shown to reduce post-weaning diarrhoea and provide similar protection to antimicrobial agents including zinc oxide as well as reduce antimicrobial resistance However, Detach® requires labour and effort to deliver the compound by drenching. BONIFF is a revised formulation that is applied to dry feed for piglets after weaning, reducing labour input and simplifying the entire process. Anatara successfully completed a piglet challenge trial which concluded that BONIFF could be considered as a replacement for a non-physiological level of zinc oxide with commercial levels of additives in a semi-moist extruded creep piglet diet.

Anatara has also developed ANR-pf, a proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method on-farm even when stock illness is a concern. Anatara successfully completed a poultry challenge trial “Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges”.

Our Animal Applications page provides further information on our Detach® development plans.